These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 38493955

  • 21. Mepolizumab for eosinophilic severe asthma: recent studies.
    Robinson DS, Kariyawasam HH.
    Expert Opin Biol Ther; 2015 Jun; 15(6):909-14. PubMed ID: 25951938
    [Abstract] [Full Text] [Related]

  • 22. Engineering of Humanized Antibodies Against Human Interleukin 5 Receptor Alpha Subunit That Cause Potent Antibody-Dependent Cell-Mediated Cytotoxicity.
    Kim JE, Lee DH, Jung K, Kim EJ, Choi Y, Park HS, Kim YS.
    Front Immunol; 2020 Jun; 11():593748. PubMed ID: 33488590
    [Abstract] [Full Text] [Related]

  • 23. The role of interleukin 5 in asthma.
    Varricchi G, Canonica GW.
    Expert Rev Clin Immunol; 2016 Sep; 12(9):903-5. PubMed ID: 27450970
    [No Abstract] [Full Text] [Related]

  • 24. Evaluation of Potential Continuation Rules for Mepolizumab Treatment of Severe Eosinophilic Asthma.
    Gunsoy NB, Cockle SM, Yancey SW, Keene ON, Bradford ES, Albers FC, Pavord ID.
    J Allergy Clin Immunol Pract; 2018 Sep; 6(3):874-882.e4. PubMed ID: 29258789
    [Abstract] [Full Text] [Related]

  • 25. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
    Ortega HG, Yancey SW, Mayer B, Gunsoy NB, Keene ON, Bleecker ER, Brightling CE, Pavord ID.
    Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
    [Abstract] [Full Text] [Related]

  • 26. Mepolizumab: First Global Approval.
    Keating GM.
    Drugs; 2015 Dec; 75(18):2163-9. PubMed ID: 26603873
    [Abstract] [Full Text] [Related]

  • 27. IL-5 and IL-5 receptor in asthma.
    Kotsimbos AT, Hamid Q.
    Mem Inst Oswaldo Cruz; 1997 Dec; 92 Suppl 2():75-91. PubMed ID: 9698919
    [Abstract] [Full Text] [Related]

  • 28. Mepolizumab and exacerbations of refractory eosinophilic asthma.
    Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, Pavord ID.
    N Engl J Med; 2009 Mar 05; 360(10):973-84. PubMed ID: 19264686
    [Abstract] [Full Text] [Related]

  • 29. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway.
    Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS.
    Am J Respir Crit Care Med; 2003 Jan 15; 167(2):199-204. PubMed ID: 12406833
    [Abstract] [Full Text] [Related]

  • 30. Serum Levels of Epithelial-Derived Cytokines as Interleukin-25 and Thymic Stromal Lymphopoietin after a Single Dose of Mepolizumab in Patients with Severe Non-Allergic Eosinophilic Asthma: A Short Report.
    Kalinauskaite-Zukauske V, Januskevicius A, Janulaityte I, Miliauskas S, Malakauskas K.
    Can Respir J; 2019 Jan 15; 2019():8607657. PubMed ID: 31885750
    [Abstract] [Full Text] [Related]

  • 31. The Possible Roles of IL-4/IL-13 in the Development of Eosinophil-Predominant Severe Asthma.
    Nakagome K, Nagata M.
    Biomolecules; 2024 May 02; 14(5):. PubMed ID: 38785953
    [Abstract] [Full Text] [Related]

  • 32. Prostaglandin D2 metabolites activate asthmatic patient-derived type 2 innate lymphoid cells and eosinophils via the DP2 receptor.
    Carstensen S, Gress C, Erpenbeck VJ, Kazani SD, Hohlfeld JM, Sandham DA, Müller M.
    Respir Res; 2021 Oct 07; 22(1):262. PubMed ID: 34620168
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia.
    Laviolette M, Gossage DL, Gauvreau G, Leigh R, Olivenstein R, Katial R, Busse WW, Wenzel S, Wu Y, Datta V, Kolbeck R, Molfino NA.
    J Allergy Clin Immunol; 2013 Nov 07; 132(5):1086-1096.e5. PubMed ID: 23866823
    [Abstract] [Full Text] [Related]

  • 36. The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study.
    McDowell PJ, Diver S, Yang F, Borg C, Busby J, Brown V, Shrimanker R, Cox C, Brightling CE, Chaudhuri R, Pavord ID, Heaney LG, Medical Research Council: Refractory Asthma Stratification Programme (RASP-UK Consortium).
    Lancet Respir Med; 2021 Oct 07; 9(10):1174-1184. PubMed ID: 33971168
    [Abstract] [Full Text] [Related]

  • 37. Benralizumab: A New Approach for the Treatment of Severe Eosinophilic Asthma.
    Dávila González I, Moreno Benítez F, Quirce S.
    J Investig Allergol Clin Immunol; 2019 Apr 07; 29(2):84-93. PubMed ID: 31017107
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics.
    Menzies-Gow A, Flood-Page P, Sehmi R, Burman J, Hamid Q, Robinson DS, Kay AB, Denburg J.
    J Allergy Clin Immunol; 2003 Apr 07; 111(4):714-9. PubMed ID: 12704348
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.